{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+protocol&page=7", "query": { "intervention": "Standard protocol", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 1955, "total_pages": 196, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+protocol&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+protocol&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T04:18:16.416Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04020185", "title": "Safety and Efficacy Study of IMSA101 in Refractory Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "IMSA101", "type": "DRUG" }, { "name": "Immune checkpoint inhibitor (ICI)", "type": "DRUG" }, { "name": "Immuno-oncology (IO) therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmuneSensor Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2019-09-23", "completion_date": "2023-09-15", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-10-22T04:18:16.416Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • La Jolla, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04020185" }, { "nct_id": "NCT00582309", "title": "Comparative Trial Between 3 Types of Insulin Infusion Protocols", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hyperglycemia" ], "interventions": [ { "name": "Glucommander-Guided Intravenous Insulin Infusion", "type": "PROCEDURE" }, { "name": "Standard Intravenous Insulin Infusion", "type": "PROCEDURE" }, { "name": "Simple Calculated Intravenous Insulin Infusion", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 151, "start_date": "2007-08", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2015-06-23", "last_synced_at": "2026-10-22T04:18:16.416Z", "location_count": 3, "location_summary": "Chicago Heights, Illinois • Albuquerque, New Mexico", "locations": [ { "city": "Chicago Heights", "state": "Illinois" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00582309" }, { "nct_id": "NCT04486378", "title": "A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer Stage II", "Colorectal Cancer Stage III" ], "interventions": [ { "name": "RO7198457 intravenous (IV)", "type": "DRUG" }, { "name": "Observational group (no intervention)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 327, "start_date": "2021-03-08", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-22T04:18:16.416Z", "location_count": 15, "location_summary": "Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04486378" }, { "nct_id": "NCT01409421", "title": "RESEARCH PROTOCOL: Glaucoma Treatment Adherence and Persistence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Primary Open Angle Glaucoma" ], "interventions": [ { "name": "motivational interviewing", "type": "BEHAVIORAL" }, { "name": "three phone calls to remind patients to take their eye drops", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2011-04", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2015-10-01", "last_synced_at": "2026-10-22T04:18:16.416Z", "location_count": 2, "location_summary": "Aurora, Colorado • Portland, Oregon", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01409421" }, { "nct_id": "NCT01001338", "title": "Allopurinol Combination Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout" ], "interventions": [ { "name": "RDEA594", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ardea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 227, "start_date": "2009-10", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2017-01-24", "last_synced_at": "2026-10-22T04:18:16.416Z", "location_count": 25, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01001338" }, { "nct_id": "NCT06564038", "title": "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukaemia", "Small Lymphocytic Lymphoma", "Mantle-cell Lymphoma", "Large B-cell Lymphoma", "B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Surovatamig", "type": "DRUG" }, { "name": "Prednisone (or equivalent)", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 408, "start_date": "2025-01-30", "completion_date": "2029-06-11", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-22T04:18:16.416Z", "location_count": 12, "location_summary": "Boston, Massachusetts • Hackensack, New Jersey • New Brunswick, New Jersey + 8 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06564038" }, { "nct_id": "NCT06483100", "title": "Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elrantamab", "type": "DRUG" }, { "name": "clonoSEQ", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2024-12-20", "completion_date": "2032-06-30", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-22T04:18:16.416Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06483100" }, { "nct_id": "NCT03431467", "title": "Impella CP With VA ECMO for Cardiogenic Shock", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiogenic Shock" ], "interventions": [ { "name": "Impella-CP LV Vent", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 17, "start_date": "2018-03-19", "completion_date": "2023-09-01", "has_results": true, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-10-22T04:18:16.416Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03431467" }, { "nct_id": "NCT07084545", "title": "Evaluation of Cataract Surgery Outcomes in Patients With Prior Laser Vision Correction Implanted With the CT LUCIA Lens", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Postoperative Visual Outcomes Following Cataract Surgery in Patients With Prior Myopic Corneal Laser Vision Correction" ], "interventions": [ { "name": "CT LUCIA 621P Intraocular Lens Implantation", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Carl Zeiss Meditec AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-07", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2025-07-24", "last_synced_at": "2026-10-22T04:18:16.416Z", "location_count": 2, "location_summary": "Sugar Land, Texas • Lynchburg, Virginia", "locations": [ { "city": "Sugar Land", "state": "Texas" }, { "city": "Lynchburg", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07084545" }, { "nct_id": "NCT01167595", "title": "Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Critically Ill" ], "interventions": [ { "name": "PEP uP Protocol", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Clinical Evaluation Research Unit at Kingston General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1059, "start_date": "2010-09", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2021-04-28", "last_synced_at": "2026-10-22T04:18:16.416Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Loveland, Colorado • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Loveland", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Clinton Township", "state": "Michigan" }, { "city": "Springfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01167595" } ] }